MedTrace Logo

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

NCT06265350 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-02-20

No results posted yet for this study

Summary

This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.

Conditions

Interventions

DRUG

Cadonilimab

Cadonilimab, 375mg，Q3W， IV

DRUG

Bevacizumab

Bevacizumab, 7.5mg/kg，Q3W， IV

PROCEDURE

Cryoablation

Patients accepted Cryoablation of pulmanary metastases

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Zhimei Hunag, MD · Sun Yat-sen University

  • Jinhua Huang, MD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-02
Primary Completion
2026-01-30
Completion
2027-01-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06265350 on ClinicalTrials.gov